XML 52 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Acquisition of EGEN Assets (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2016
Jun. 20, 2014
Jun. 20, 2014
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Asset impairment charges, total                 $ 2,400,000      
Business Combination, Consideration Transferred, Liabilities Incurred                     $ 4,500,000 $ 2,500,000
Finite-lived intangible assets, net, ending balance           $ 454,634     454,634   568,292  
Aspire Purchase Agreement [Member]                        
Finite-lived intangible assets, net, ending balance           454,634     454,634   568,929  
Finite-lived intangible assets, accumulated amortization           1,136,580     1,136,580   1,022,922  
IPR&D Drug Technology Platforms [Member]                        
Asset impairment charges, total     $ 1,400,000                  
EGEN Inc [Member]                        
Potential future earn-out payments       $ 30,400,000 $ 30,400,000              
Payments to Acquire Businesses, Gross       $ 3,000,000                
Stock issued during period, shares, acquisitions       241,590                
Business Combination, Consideration Transferred, Liabilities Incurred         13,900,000     $ 12,800,000   $ 13,100,000   $ 12,500,000
Goodwill, acquisition                 2,000,000      
EGEN Inc [Member] | Purchase Agreement [Member]                        
Finite-lived intangible assets acquired                 $ 1,600,000      
Finite-lived intangible asset, useful life                 7 years      
Amortization expense           56,829 $ 56,829   $ 113,658 $ 113,658    
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]                        
Asset impairment charges, total $ 9,400,000 $ 9,400,000                    
EGEN Inc [Member] | Ovarian Cancer [Member]                        
Finite-lived intangible assets, net, ending balance           $ 13,300,000     13,300,000   $ 13,300,000  
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]                        
Indefinite lived intangible assets                 $ 24,200,000      
EGEN Inc [Member] | Maximum [Member]                        
Total purchase price for the asset acquisition       $ 44,400,000                
Potential future earn-out payments       $ 30,400,000 $ 30,400,000